Clinical Trial Update: Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a radiolabeled monoclonal antibody with paclitaxel and interferon alfa in patients with recurrent ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Interferon Alfa (interferon alfa)
• PACLITAXEL (PACLITAXEL)
• Radiolabeled monoclonal antibody

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer | Phase 1 | Status: COMPLETED